BG
CDTX

Bellevue Group’s Cidara Therapeutics CDTX Stock Holding History

Bellevue Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-141,125
Closed -$5.64M – 222
2020
Q4 		$5.64M Hold
141,125
– – 0.06% 124
2020
Q3 		$8.04M Hold
141,125
– – 0.11% 115
2020
Q2 		$10.4M Hold
141,125
– – 0.15% 104
2020
Q1 		$7M Buy
141,125
+26,361
+23% +$1.58M 0.14% 103
2019
Q4 		$8.81M Hold
114,764
– – 0.14% 99
2019
Q3 		$4.58M Hold
114,764
– – 0.09% 112
2019
Q2 		$3.86M Buy
+114,764
New +$4.77M 0.07% 112

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group's CDTX Position: Q1 2021 in Review

Bellevue Group sold out of Cidara Therapeutics (CDTX) in Q1 2021, closing a stake of 141,125 shares — an estimated $5.64M sold.

Bellevue Group first reported a position in CDTX in Q2 2019 and held it in 7 quarters. The position peaked at $10.4M in Q2 2020. 62 funds tracked by Wall St. Rank hold CDTX as of Q1 2021.

  • Bellevue Group reported no remaining Cidara Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Bellevue Group sold 141,125 Cidara Therapeutics shares in Q1 2021, an estimated $5.64M.
  • Bellevue Group first reported a position in Cidara Therapeutics in Q2 2019 and held it in 7 quarters.
  • Bellevue Group's Cidara Therapeutics position peaked at $10.4M in Q2 2020.
  • 62 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2021.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.